XASEAZTR
Market cap3mUSD
Dec 23, Last price
0.42USD
1D
1.16%
1Q
-24.50%
IPO
-99.69%
Name
Azitra Inc
Chart & Performance
P/E
—
P/S
4.67
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
686k
+141.55%
Net income
-11m
L+5.65%
CFO
-7m
L-11.82%
Profile
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | |||
Revenues | 686 141.55% | 284 158.18% | 110 |
Cost of revenue | 8,728 | 10,144 | 9,416 |
Unusual Expense (Income) | |||
NOPBT | (8,042) | (9,860) | (9,306) |
NOPBT Margin | |||
Operating Taxes | 17 | (728) | 174 |
Tax Rate | |||
NOPAT | (8,059) | (9,132) | (9,481) |
Net income | (11,284) 5.65% | (10,680) 19.47% | (8,940) |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 5,991 | 2 | 8 |
BB yield | -53.83% | ||
| Debt | |||
Debt current | 645 | 287 | |
Long-term debt | 1,450 | 8,569 | 992 |
Deferred revenue | |||
Other long-term liabilities | 35 | 33,765 | 33,766 |
Net debt | 298 | 5,364 | (7,052) |
| Cash flow | |||
Cash from operating activities | (7,362) | (8,349) | (8,067) |
CAPEX | (27) | (160) | (456) |
Cash from investing activities | (318) | (337) | (652) |
Cash from financing activities | 5,984 | 4,135 | 993 |
FCF | (7,778) | (10,149) | |
| Balance | |||
Cash | 1,796 | 3,493 | 8,044 |
Long term investments | |||
Excess cash | 1,762 | 3,478 | 8,039 |
Stockholders' equity | (43,482) | (37,313) | (26,633) |
Invested Capital | 47,961 | 42,546 | 35,623 |
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | 403 | 403 | 403 |
Price | 27.60 | ||
Market cap | 11,130 | ||
EV | 16,543 | ||
EBITDA | (7,616) | (9,454) | (9,221) |
EV/EBITDA | |||
Interest | 168 | 252 | 67 |
Interest/NOPBT | |||